Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

NCT Number	NCT07301008
Lead Sponsor	Medstar Health Research Institute Collaborators: Pfizer
Conditions	Migraine, Trigger Induced Migraine
Enrollment	60 participants
Start Date	2025-09-09
Primary Completion	2026-09 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-24